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• Venous thromboembolism (VTE), which includes deep-vein
thrombosis (DVT) and pulmonary embolism (PE), leads to
60,000-100,000 deaths annually in the United States1
• Weight-based heparin protocols are the mainstay for treatment
of VTE
• Dosing recommendations in the morbidly obese population
remains highly controversial
• Previous studies have shown that a therapeutic activated partial
thromboplastin time (aPTT) within 24 hours of initiating
unfractionated heparin (UFH) therapy results in decreased longterm recurrence of venous thromboembolism (VTE) 2,3
• Current guidelines recommend weight-based heparin dosing,
but they do not specify type of dosing weight to be used or
maximum bolus dose and initial infusion rate for the treatment
of VTE2,3,4

Purpose
• Evaluate and compare the time to goal aPTT in patients with
body mass index (BMI) ≤ 40 kg/m2 and BMI > 40 kg/m2,
receiving UFH therapy per VTE weight-based protocol at HCA
Houston Healthcare Clear Lake

• Retrospective, single-center, chart review
• Data collection using electronic medical records and pharmacy
surveillance software
• Data time range: July 1, 2019 to June 30, 2021

Above all else, we are committed to the care and improvement of human life
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Conclusion

• Pregnancy

• Average time to first goal aPTT for BMI ≤ 40 kg/m2 was 18.4
hours and for BMI > 40 kg/m2 was 16.3 hours
• 1 bleeding event each in both groups
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Figure 1. Percentage of aPTT levels

Preliminary Results

• Time to first goal aPTT (60-80 sec)
• Occurrence of bleeding event
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Exclusion

• Adults ≥ 18 years of age
• Received heparin infusion for
≥ 12 hours
• Treated using the VTE
heparin protocol

BMI > 40 kg/m2

25 patients with BMI
< 30 kg/m2

50 patients were
selected for
BMI > 40 kg/m2
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Primary Efficacy and Safety Outcome

• Time to first goal aPTT with initial bolus versus no bolus
• Time to first goal aPTT with dose capping versus no dose
capping
• Time to steady-state defined as two consecutive therapeutic
aPTT readings
• Heparin dose at first goal aPTT and steady-state
• Protocol compliance with initial UFH rate
• Percentage of subtherapeutic, therapeutic, and supratherapeutic
aPTT levels at the time ranges of 0-12 hours, 12-24 hours, and
24- 48 hours
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Table 1. Secondary Endpoint Results
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